{"_id":"4f4Evk6AA1I9ro0r8IfJq5dunrLgWjWIbY3nX64eGPVnUh17VP1tzK","lastupdate":"2024-10-01T00:00:00.000Z","update_date":"2024-10-01T00:00:00.000Z","lastModified":"Oct 1, 2024","active":1,"confidence_score":80,"confidence_score_reason":"sector, video or image, funding rounds, markets, not claimed","urlname":"impact-biotech","minimal_profile":null,"status":"","fullstatus":"","acquired":null,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$NpkxYwYQUcdBzEVCBdrKvd2vttaiOSNFcAucmb3PLdniV33c7Vmk0U.png","name":"ImPact Biotech","oneliner":"Targeted Treatment for Selective Tumor Ablation","registrar":"513381319","website":"https://impactbiotech.com/","careerspage":"","founded_month":1,"founded_year":1996,"formernames":["Steba Biotech"],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/71243727","instagram":""},"social":["https://www.linkedin.com/company/71243727"],"flattenedsociallinks":"https://www.linkedin.com/company/71243727","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":40,"patent":1,"raised":2700000,"stage":"Pre-Funding","public_stage":"Pre-Funding","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"ImPact Biotech is focused on the development and launch of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a targeted treatment for selective tumor ablation. Padeliporfin VTP therapy is a novel Oncology technology platform that comprises the intravenous delivery of an inactive drug, Padeliporfin, which is then precisely activated only in the tumor micro-environment by non-thermal laser light delivered via optical fiber(s). This results in the immediate occlusion of the tumor blood supply followed by self-propagating immunogenic cell death and immune activation with minimal effect on surrounding healthy tissues.\n\nImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in VTP.","climatetech_description":null,"is_climatetech_relevant":null,"phone":null,"country":null,"address":{"israeli":[{"id":"aP9pLK46ycDMxOrPdB67JuePxRaYvTMCVCCuhoTr4o1HordyISZhGY","city":"Ness Ziona","type":null,"address":"Ness Ziona, Israel","placeid":"ChIJJbOI0Za2AhURJ70ufX-3YZo","notactive":null,"openeddate":null,"registrarid":null,"firstrdcenter":null,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"fR3DfkJjRdAnG9BxwYRZ4T3kx4s39pdKunfRyKl1RT3i6WFnDXk2dP","date":"Sep 26, 2024","link":"https://www.globenewswire.com/news-release/2024/09/27/2954460/0/en/ImPact-Biotech-Announces-50-Enrollment-in-Phase-3-ENLIGHTED-Clinical-Trial-of-Padeliporfin-VTP-in-Low-Grade-Upper-Tract-Urothelial-Cancer.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"ImPact Biotech","layoffs":null,"summary":"ImPact Biotech announced that its Phase 3 ENLIGHTED trial for Padeliporfin VTP in treating low-grade UTUC has reached 50% patient enrollment. The company expects to complete enrollment by Q1 2025. Interim results showed a 77% complete response rate among evaluable patients. The European Innovation Council has made a substantial investment commitment to support the trial. ImPact Biotech collaborates with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center.","partners":["Weizmann Institute of Science","Memorial Sloan Kettering Cancer Center"],"customers":null,"investors":["European Innovation Council"],"confidence":10,"key_topics":["Phase 3","ENLIGHTED study","Padeliporfin","UTUC","investment"],"date_of_event":"2024-09-27","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RpTju5baKTlkuZvpSlURMXNRp8GPX6oSaNOL2UozgQH2ghAruF3erC","news_summary":"ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"34Ap0L5wxusXKfgY3WtCQZ6P0IzjzDWi3ehqtR39usADZXAES7t8Qf","date":"Sep 24, 2024","link":"https://www.globenewswire.com/news-release/2024/09/25/2953337/0/en/ImPact-Biotech-to-Present-at-Oppenheimer-Private-Life-Sciences-Company-Showcase.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"presentation","company":"ImPact Biotech","layoffs":null,"summary":"ImPact Biotech, a clinical-stage biotechnology company specializing in Padeliporfin vascular targeted photodynamic (VTP) therapy for solid tumors, announced that its management will present a corporate overview at the Oppenheimer Private Life Sciences Company Showcase on October 1st, 2024, in New York, NY. The presentation will be delivered by CEO Barak Palatchi. The company is also hosting one-on-one meetings at the conference. ImPact Biotech is currently evaluating its VTP therapy in a pivotal Phase 3 study for low-grade upper tract urothelial carcinoma (UTUC) and has ongoing or planned studies for other cancers. The company collaborates with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center.","partners":["Weizmann Institute of Science","Memorial Sloan Kettering Cancer Center"],"customers":[],"investors":[],"confidence":10,"key_topics":["presentation","conference","therapy","clinical trials","collaborations"],"date_of_event":"2024-10-01","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"14hudGe8oWkAzQjBNf0noxmhOSdKLmQ0RVLRogtftMqpFjnLZTsAwh","news_summary":"ImPact Biotech to Present at Oppenheimer Private Life Sciences Company Showcase","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"MGThkf967PFaf8h2n25XhYWqmdUW1xfG53TvJLx74TRfOFoD5hgq62","date":"May 5, 2024","link":"https://www.globenewswire.com/news-release/2024/05/06/2875744/0/en/ImPact-Biotech-Presents-Preliminary-Phase-3-Results-from-ENLIGHTED-Study-of-Padeliporfin-VTP-in-Low-Grade-Upper-Tract-Urothelial-Cancer.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical-trial","company":"ImPact Biotech","layoffs":null,"summary":"ImPact Biotech announced positive preliminary results from its Phase 3 ENLIGHTED clinical trial evaluating Padeliporfin VTP for treating low-grade upper tract urothelial cancer (UTUC). The treatment showed a 67% complete response rate in patients who completed the Induction Treatment Phase and was well-tolerated. These results were presented at the American Urology Association (AUA) 2024 Annual Meeting. The company plans to continue recruiting patients and expects to complete enrollment by the end of 2024. ImPact Biotech also aims to evaluate Padeliporfin VTP in other solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).","partners":[],"customers":[],"investors":[],"confidence":10,"key_topics":["clinical-trial","UTUC","Padeliporfin","Phase 3","results"],"date_of_event":"May 06, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mVmhA6jvQR8CDyeNwgl7WCuWhYVlmGHMI9kAcEYpLa3Q0MfV0xVID8","news_summary":"ImPact Biotech Presents Preliminary Phase 3 Results from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hrink8FMUkDytSTpSW7sysSE87JIS1ARWRTKMawnvbbJyf8mNLYVbr","date":"Dec 19, 2023","link":"https://finance.yahoo.com/news/impact-biotech-receives-fda-clearance-130000767.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","company":"ImPact Biotech","layoffs":null,"summary":"ImPact Biotech announced that its Investigational New Drug (IND) application for Padeliporfin Vascular Targeted Photodynamic (VTP) therapy has been cleared by the FDA to begin a Phase 1 study in patients with unresectable pancreatic adenocarcinoma (PDAC). The study, expected to start in the first half of 2024, aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the therapy. This clearance reflects the broad potential of Padeliporfin VTP across various solid tumors. The company is also conducting studies in upper tract urothelial cancer and plans to evaluate the therapy in non-small cell lung cancer.","partners":["Weizmann Institute of Science","Memorial Sloan Kettering Cancer Center"],"customers":["patients with unresectable pancreatic adenocarcinoma"],"investors":[],"confidence":10,"key_topics":["clinical trial","FDA clearance","oncology","solid tumors","Padeliporfin VTP"],"date_of_event":"2023-12-20","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8bhXOsGlCctl0Da93OlaJeqjTVlyUXlr52GJKQnFao2JiF6Ejewx45","news_summary":"ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"pDnX48z4p8dmT0MNAxgKyAmv9HrZvioU8vsgwPb8SmMOS3wBnCVbi5","date":"Aug 14, 2023","link":"https://www.bioworld.com/articles/699979-impact-biotech-collaborates-with-maastricht-university-to-advance-padeliporfin-vtp-research-for-pathological-myopia?v=preview","source":"www.bioworld.com","visible":1,"analysis":{"tags":"collaboration","company":"Impact Biotech Ltd.","layoffs":"","summary":"Impact Biotech Ltd. has entered into a collaboration with Maastricht University to advance research on using padeliporfin vascular targeted photodynamic (VTP) therapy to treat pathological myopia, also known as myopic macular degeneration. This partnership aims to arrest the progression of this eye condition, leveraging Impact Biotechs VTP therapy platform.","partners":"Maastricht University","customers":"","investors":"","confidence":10,"key_topics":["collaboration","research","eye treatment","myopia","therapy"],"date_of_event":"August 14, 2023","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Partners"],"acquisition_amount":"","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0HhHIykvV7o2b4N9nyNkGlkHxkLglGHl93BJNjvGXxIeutywlxi42K","news_summary":"Impact Biotech collaborates with Maastricht University to advance padeliporfin VTP research for pathological myopia","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"HIEcCqFZH9MhK7SseP2N2zrgPPb2wrQSvjZqkmVaPh0PxxNeCsrI6y","date":"Jul 5, 2023","link":"https://www.pharmaceutical-technology.com/news/fda-grants-orphan-drug-designation-to-impacts-focal-cancer-therapy/","source":"www.pharmaceutical-technology.com","visible":1,"analysis":{"tags":"orphan drug","company":"ImPact Bio","layoffs":null,"summary":"The FDA has granted orphan drug designation to ImPact Bios padeliporfin VTP for treating locally advanced pancreatic cancer. The company, headquartered in Israel, plans to submit an IND application and start a Phase I trial later in 2023. Orphan drug designation provides benefits such as tax credits for US-based clinical trials and FDA recommendations on necessary studies. The therapy involves using padeliporfin activated by non-thermal laser light to target tumors. ImPact Bio is a spin-off from Steba Biotech, which initially developed the treatment.","partners":[],"customers":["patients with locally advanced pancreatic cancer"],"investors":[],"confidence":10,"key_topics":["FDA","orphan drug","pancreatic cancer","therapy","trial"],"date_of_event":"2023-07-05","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xf10z5v6wBTm8dX0CZxum3df2KSoKjLitFPzWqwBiFLpxKDRNHDxdy","news_summary":"FDA grants orphan drug designation to ImPact’s focal cancer therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":6,"techcommunityinvolvement":null,"mediagallery":[],"tags":["biotechnology","oncology","cancer-therapy","pharmaceuticals","immunotherapy","cancer","minimally-invasive"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["Padeliporfin VTP"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"$2.7M","totalrounds":1,"fundingstage":"Pre-Funding","totalfunding":"$2.7M","publicinvestors":0,"lastpublicfunding":2700000,"totalpublicrounds":1,"totalpublicfunding":2700000},"team":[{"name":"Barak  Palatchi","email":"barak.palatchi@impactbiotech.com","phone":"","gender":"Male","userid":"4tQOIjCM29dcRxzQfl6ipkXrpryqwmaqQ4TROVLeAowpZoAOJn5FGv","bounced":false,"claimed":null,"founder":0,"urlname":"barak-palatchi","visible":1,"memberid":"MHQhQNVdgYd8JEBzfzZecuD8kMUKlywO0XaPbuI0uEuqk6TXmtKPWb","position":"CEO","last_name":"Palatchi","claimtoken":"lATrJzuQub6xsSs668n2M4A373tiKTIpzUF3uYc8G4TSGQSdLYh42v","first_name":"Barak ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/barak-palatchi-29699a260/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-10-01 13:31:46.000000","initials":"BP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eyal Morag","email":"eyal.morag@impactbiotech.com","phone":"","gender":"Male","userid":"uMUoyyNL7738PDAQu96Iy6pmIuVSWDH0Es9Tl545AyDHHIa2DaC3LC","bounced":false,"claimed":null,"founder":0,"urlname":"eyal-morag-2","visible":1,"memberid":"Fba7zFPsrpXk3dlVLCStRtGk7lW4D7WG5CmsnYs1P3mF1O6ZEvOMDA","position":"CMO","last_name":"Morag","claimtoken":"Rcqc08T6LudXLmsBR8AkV9q7c3bBxJiIoSz7XS5enGaDx3QIMgtfob","first_name":"Eyal","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dr-eyal-morag-77377723/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-10-01 13:34:15.000000","initials":"EM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Guy  Schmidt","email":"guy.schmidt@impactbiotech.com","phone":"","gender":"Male","userid":"09Ljq6Pe5qdHcGnjWZH8ltMsmVhnu5r9EFq4PYW3hyLHTCqjXi1k5p","bounced":false,"claimed":null,"founder":0,"urlname":"guy-schmidt","visible":1,"memberid":"Hqpu5gFvtDCfJ5IsXXVhEwmSHOVbFbFAyTwKhF8eBpPnaTflii5T6P","position":"Global Head of Business Development","last_name":"Schmidt","claimtoken":"qt0rpTDPhQWnz9Y3iOACL8uclKvhjwxvBhPqmiEtl7b2bv6fXAQL4P","first_name":"Guy ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/guy-schmidt-6700002/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-10-01 13:39:54.000000","initials":"GS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Orit  Schwartz","email":"orit.schwartz@impactbiotech.com","phone":"","gender":"Female","userid":"iGaNAUqBzuaekSv050cqxlSMn3MTXIkymcb6gvilfUVVK7PIde2cqg","bounced":false,"claimed":null,"founder":0,"urlname":"orit-schwartz","visible":1,"memberid":"LTOI6HkwHm4kQSLfoNIzFRoAuSrZ9EpP5qvU23N3jNeIka0EkpWtBA","position":"Global Head of Technical Operations","last_name":"Schwartz","claimtoken":"fcTwHhzFJ8MLxxCBWmHaJXJL1GDvR5QpAipmRi6d7g5wRreOJWiQVP","first_name":"Orit ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/orit-schwartz-99a83011/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-10-01 13:33:11.000000","initials":"OS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":null,"tag_line_edited":null,"sector":null,"sectorverify":null,"biverify":{"id":"c9EsgAuuvwml0IzyIKWmOxLUUF5GjptiIXjHR1tp2gTB0O2GoGTfCd","fullname":"Yanina Wainscheinker"},"biverifydate":"2024-10-01T00:00:00.000Z","crunchbaseid":null,"lastupdator":null,"lastupdator_email":null,"creator":"Yanina Wainscheinker","creator_email":"yanina.wainscheinker@sncentral.org","createdate":"2024-10-01T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"3726ums0BH1cJX8hWcqJLKSdo3121i9PYjAdrc4xhuBQTMCgx0cFa5","date":"Jul 2024","amount":"$2.7M","source":"","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"European Innovation Council","type":"Investor","amount":null,"hidden":false,"country":"Belgium","fullurl":"/investor_page/european-innovation-council","logokey":"$BM8t5Nw7HzAiqGbGUipDDhCefh8oinehng6mftX5R55QqxvAAyPLau","tagline":"","urlname":"/investor_page/european-innovation-council","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC7qIihCww","fundingtype":"Incubator","leadpartner":null,"investmentid":"9T3skSWxAkqT8YfEckOMJyXIeQ5UAqItKIUHR7eNsTxekNudCyPy3t","fundingsubtype":"Incubator","investorislead":1,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BM8t5Nw7HzAiqGbGUipDDhCefh8oinehng6mftX5R55QqxvAAyPLau","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/1996","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"ImPact Biotech","logourl":"https://storage.googleapis.com/clean-finder-353810/$NpkxYwYQUcdBzEVCBdrKvd2vttaiOSNFcAucmb3PLdniV33c7Vmk0U.png","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$NpkxYwYQUcdBzEVCBdrKvd2vttaiOSNFcAucmb3PLdniV33c7Vmk0U.png","seoabout":"ImPact Biotech is focused on the development and launch of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a targeted treatment for selective tu...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[{"id":"3726ums0BH1cJX8hWcqJLKSdo3121i9PYjAdrc4xhuBQTMCgx0cFa5","date":"Jul 2024","amount":"$2.7M","source":"","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"European Innovation Council","type":"Investor","amount":null,"hidden":false,"country":"Belgium","fullurl":"/investor_page/european-innovation-council","logokey":"$BM8t5Nw7HzAiqGbGUipDDhCefh8oinehng6mftX5R55QqxvAAyPLau","tagline":"","urlname":"/investor_page/european-innovation-council","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC7qIihCww","fundingtype":"Incubator","leadpartner":null,"investmentid":"9T3skSWxAkqT8YfEckOMJyXIeQ5UAqItKIUHR7eNsTxekNudCyPy3t","fundingsubtype":"Incubator","investorislead":1,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$BM8t5Nw7HzAiqGbGUipDDhCefh8oinehng6mftX5R55QqxvAAyPLau","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}